Čestmír Neoral

Čestmír Neoral

Auto-generated profile, based on publicly available information

Čestmír Neoral

1st Clinic of Surgery, Medical Faculty, Palacký University Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DVDavid Vrana
David Vrana
MMMarcel Matzenauer
Marcel Matzenauer
ČNČestmír Neoral
Čestmír Neoral
RARené Aujeský
René Aujeský
RVRadek Vrba
Radek Vrba
JJJanusz Jankowski
Janusz Jankowski
Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome. Immunotherapy with checkpoint inhibitors is a novel treatment approach that quickly entered clinical practice in malignant melanoma and renal cell cancer, but the role in esophageal and gastric cancer is still poorly defined. The principal prognostic/predictive biomarkers for immunotherapy efficacy currently considered are PD-L1 expression along with defects in mismatch repair genes resulting in microsatellite instability (MSI-H) phenotype. The new molecular classification of gastric cancer also takes these factors into consideration. Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications. The most important recently published clinical trials evaluating checkpoint inhibitor efficacy in these tumors are also summarized.

7 January 2011 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
MČMarie Černá
Marie Černá
MKMartin Köcher
Martin Köcher
VVVlastimil Válek
Vlastimil Válek
RARené Aujeský
René Aujeský
ČNČestmír Neoral
Čestmír Neoral
SMShankari Mahathmakanthi
Shankari Mahathmakanthi

Verified
Journal Article
Open access
PDF file
DVDavid Vrana
David Vrana
VHViktor Hlavac
Viktor Hlavac
VBVeronika Brynychova
Veronika Brynychova
RVRadka Vaclavikova
Radka Vaclavikova
CNCestmir Neoral
Cestmir Neoral
Pavel SoucekPavel Soucek
Pavel Soucek
The prognosis of esophageal cancer (EC) is poor, despite considerable effort of both experimental scientists and clinicians. The tri-modality treatment consisting of neoadjuvant chemoradiation followed by surgery has remained the gold standard over decades, unfortunately, without significant progress in recent years. Suitable prognostic factors indicating which patients will benefit from this tri-modality treatment are missing. Some patients rapidly progress on the neoadjuvant chemoradiotherapy, which is thus useless and sometimes even harmful. At the same time, other patients achieve complete remission on neoadjuvant chemoradiotherapy and subsequent surgery may increase their risk of morbidity and mortality. The prognosis of patients ranges from excellent to extremely poor. Considering these differences, the role of drug metabolizing enzymes and transporters, among other factors, in the EC response to chemotherapy may be more important compared, for example, with pancreatic cancer where all patients progress on chemotherapy regardless of the treatment or disease stage. This review surveys published literature describing the potential role of ATP-binding cassette transporters, the genetic polymorphisms, epigenetic regulations, and phenotypic changes in the prognosis and therapy of EC. The review provides knowledge base for further research of potential predictive biomarkers that will allow the stratification of patients into defined groups for optimal therapeutic outcome.

1 November 1998 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MKMartin Köcher
Martin Köcher
MDMichael Dlouhy
Michael Dlouhy
CNCestmir Neoral
Cestmir Neoral
EBEva Buriankova
Eva Buriankova
AGAdolf Gryga
Adolf Gryga
RARene Aujesky
Rene Aujesky

1 July 2011 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
TPTomáš Papajík
Tomáš Papajík
MMMiroslav Mysliveček
Miroslav Mysliveček
ZŠZuzana Šedová
Zuzana Šedová
EBEva Buriánková
Eva Buriánková
VPVít Procházka
Vít Procházka
KIKarel Indrák
Karel Indrák
Cases of synchronous non-Hodgkin lymphoma (NHL) and second primary carcinoma in previously untreated immunocompetent patients are relatively rare. The aim of this part of our prospective study was to a revealed 2-F-18 fluoro-2-deoxy-D-glucose (F-18 FDG) positron emission tomography (PET)-positive lesion in an extranodal organ suggestive of second primary neoplasm in newly diagnosed NHL patients. A total of 209 patients with NHL underwent initial staging F-18 FDG PET/computed tomography (CT). The finding was assessed by a radiologist, nuclear medicine physician, and hematologist. In 6 suspicious cases (2.9%) of second neoplasm, the decision was made to perform further investigations before lymphoma therapy. Two patients were diagnosed with colorectal carcinoma, 1 with esophageal adenocarcinoma, 1 with invasive ductal breast carcinoma, 1 with medullary thyroid carcinoma, and 1 with squamous cell lung carcinoma. In 5 of the 6 patients, the second solid tumor was completely asymptomatic and revealed only by F-18 FDG PET/CT examination. We conclude that in patients with NHL, appropriate imaging, clinical, and histologic analysis of organ lesions detected by F-18 FDG PET/CT will occasionally demonstrate significant synchronous neoplasms.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FČFilip Čečka
Filip Čečka
MLMartin Loveček
Martin Loveček
BJBohumil Jon
Bohumil Jon
PSPavel Skalický
Pavel Skalický
ZŠZdeněk Šubrt
Zdeněk Šubrt
AFAlexander Ferko
Alexander Ferko
AIM: To study all the aspects of drain management in pancreatic surgery. METHODS: We conducted a systematic review according to the PRISMA guidelines. We searched the Cochrane Central Registry of Controlled Trials, EMBASE, Web of Science, and PubMed (MEDLINE) for relevant articles on drain management in pancreatic surgery. The reference lists of relevant studies were screened to retrieve any further studies. We included all articles that reported clinical studies on human subjects with elective pancreatic resection and that compared various strategies of intra-abdominal drain management, such as drain vs no drain, selective drain use, early vs late drain extraction, and the use of different types of drains. RESULTS: A total of 19 studies concerned with drain management in pancreatic surgery involving 4194 patients were selected for this systematic review. We included studies analyzing the outcomes of pancreatic resection with and without intra-abdominal drains, studies comparing early vs late drain removal and studies analyzing different types of drains. The majority of the studies reporting equal or superior results for pancreatic resection without drains were retrospective and observational with significant selection bias. One recent randomized trial reported higher postoperative morbidity and mortality with routine omission of intra-abdominal drains. With respect to the timing of drain removal, all of the included studies reported superior results with early drain removal. Regarding the various types of drains, there is insufficient evidence to determine which type of drain is more suitable following pancreatic resection. CONCLUSION: The prophylactic use of drains remains controversial. When drains are used, early removal is recommended. Further trials comparing types of drains are ongoing.